Haas F J, van Sterkenburg-Kamp B M, Scheepers H A
St. Antonius Hospital, Nieuwegein, The Netherlands.
Semin Thromb Hemost. 1998;24(4):355-62. doi: 10.1055/s-2007-996023.
A new automated method for screening defects in the Protein C Pathway (PCP) was evaluated. The "PCP test" is based on a phospholipid-rich Russells viper venom reagent, insensitive to heparin and lupus anticoagulants. To minimize interference from other clotting variables, ratios of the clotting time with and without the addition of a protein C activator were usually determined. Plasma samples from healthy volunteers, patients untreated or on oral anticoagulants, patients with factor V Leiden with and without treatment, and patients with protein C and/or S deficiencies were tested. Mixing patient plasmas 1:1 with individual plasmas deficient in factor V, protein C or S was evaluated for identifying the nature of defects by shortening the screening test. The PCP test was found to be sensitive to APC resistance due to factor V Leiden and by mixing with factor V deficient plasma was also useful despite the effects of oral anticoagulants. Results in the group of patients with previous low protein C or S levels suggest that the method has a better sensitivity to protein C than to protein S deficiency. The automated test was simple to use and gave a between-run coefficient of variation below 3% on normal plasmas.
一种用于筛查蛋白C途径(PCP)缺陷的新型自动化方法得到了评估。“PCP检测”基于富含磷脂的罗素蝰蛇毒试剂,对肝素和狼疮抗凝物不敏感。为了将其他凝血变量的干扰降至最低,通常会测定加入和不加入蛋白C激活剂时的凝血时间比值。对健康志愿者、未接受治疗或正在接受口服抗凝治疗的患者、有或无治疗的因子V莱顿突变患者以及蛋白C和/或S缺乏患者的血浆样本进行了检测。将患者血浆与缺乏因子V、蛋白C或S的个体血浆按1:1混合,以通过缩短筛查试验来确定缺陷的性质。发现PCP检测对因子V莱顿突变导致的活化蛋白C抵抗敏感,并且尽管口服抗凝剂有影响,但与缺乏因子V的血浆混合时也很有用。先前蛋白C或S水平较低的患者组的结果表明,该方法对蛋白C缺乏的敏感性比对蛋白S缺乏的敏感性更好。该自动化检测使用简便,正常血浆的批间变异系数低于3%。